Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
62 studies found for:    Open Studies | "Oropharyngeal Neoplasms"
Show Display Options
Download search resultsDownload the search results for:
Open Studies | "Oropharyngeal Neoplasms" (62 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Unknown  Cetuximab & Concomitant-Boost Accelerated RT in Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma.
Condition: Oropharyngeal Neoplasms
Intervention: Drug: Cetuximab
2 Unknown  Analgesia of Fibula Free Flap Donor Site by Peri-Neuronal Catheter in Oro-Pharyngeal Carcinoma Surgery
Condition: Oropharyngeal Neoplasms
Intervention: Device: Peri-Neuronal Catheter
3 Not yet recruiting Paclitaxel, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
Conditions: Carcinoma, Squamous;   Squamous Cell Carcinoma;   Oropharyngeal Neoplasms;   Oropharyngeal Cancer
Interventions: Drug: cisplatin;   Drug: paclitaxel;   Drug: BYL719
4 Recruiting Post Operative Adjuvant Therapy De-intensification Trial for Human Papillomavirus-related, p16+ Oropharynx Cancer
Condition: Oropharyngeal Neoplasms
Interventions: Radiation: Intensity-modulated radiation therapy (IMRT);   Drug: Cisplatin
5 Recruiting De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study
Conditions: Carcinoma, Squamous Cell;   Head and Neck Neoplasms;   Oropharyngeal Neoplasms
Interventions: Radiation: Intensity Modulated Radiotherapy (IMRT);   Drug: Cisplatin (or alternative);   Procedure: Assessment for surgical evaluation
6 Recruiting A Post-Market Clinical Trial for Access and Visualization of the Oropharynx and Hypopharynx During Transoral Procedures
Conditions: OSA;   Oral Disease;   Oropharyngeal Neoplasms;   Hypopharyngeal Neoplasms
Intervention:
7 Recruiting Monitoring of Oral Human Papillomavirus Infection (HPV) in HPV-positive Oropharyngeal Squamous Cell Carcinoma (OPSCC)
Conditions: Carcinoma, Squamous Cell;   Head and Neck Neoplasms;   Oropharyngeal Neoplasms
Intervention: Other: Assessment of Oral HPV Infection
8 Recruiting 18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Male Breast Cancer;   Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Adult Brain Tumor;   Recurrent Basal Cell Carcinoma of the Lip;   Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Hypopharyngeal Cancer;   Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Laryngeal Cancer;   Recurrent Lip and Oral Cavity Cancer;   Recurrent Lymphoepithelioma of the Nasopharynx;   Recurrent Lymphoepithelioma of the Oropharynx;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Mucoepidermoid Carcinoma of the Oral Cavity;   Recurrent Nasopharyngeal Cancer;   Recurrent Non-small Cell Lung Cancer;   Recurrent Oropharyngeal Cancer;   Recurrent Pancreatic Cancer;   Recurrent Paranasal Sinus and Nasal Cavity Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Salivary Gland Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Stage IV Non-small Cell Lung Cancer;   Stage IV Pancreatic Cancer;   Stage IV Renal Cell Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVA Salivary Gland Cancer;   Stage IVB Colon Cancer;   Stage IVB Salivary Gland Cancer;   Stage IVC Salivary Gland Cancer;   Tongue Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Radiation: fludeoxyglucose F 18;   Radiation: 2-fluoropropionyl-labeled pegylated dimeric RGD peptide;   Procedure: positron emission tomography;   Procedure: computed tomography;   Other: laboratory biomarker analysis
9 Recruiting Adaptative Radiotherapy to Decrease Xerostomia in Oropharynx Carcinoma
Condition: Oropharynx Cancer
Intervention: Radiation: adaptative radiotherapy
10 Recruiting Laser Mucite ORL : Effectiveness of Laser Therapy for Mucositis Induced by a Radio-chemotherapy in Head and Neck Cancer
Conditions: Oral Squamous Cell Carcinoma;   Squamous Cell Carcinoma of Oropharynx;   Squamous Cell Carcinoma of Hypopharynx;   Oral Mucositis
Interventions: Procedure: low level laser therapy;   Procedure: placebo (laser low level energy nonfunctional)
11 Recruiting Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Condition: Squamous Cell Carcinoma of the Oropharynx, Larynx, or Hypopharynx
Interventions: Drug: Cisplatin;   Radiation: IMRT;   Drug: Docetaxel;   Drug: Cetuximab
12 Recruiting Radiation Therapy and Cisplatin With or Without Surgery in Treating Patients With Stage III-IV Oropharyngeal Cancer
Conditions: Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Tongue Cancer
Interventions: Procedure: therapeutic conventional surgery;   Radiation: intensity-modulated radiation therapy;   Drug: cisplatin;   Procedure: quality-of-life assessment;   Other: laboratory biomarker analysis
13 Recruiting A Phase II Study In Patients With Advanced Head And Neck Cancer Of Standard Chemoradiation And Add-On Cetuximab
Conditions: Oropharyngeal Cancer;   Hypopharyngeal Cancer;   Laryngeal Cancer
Intervention: Drug: Cetuximab
14 Recruiting Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer
Conditions: Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Salivary Gland Squamous Cell Carcinoma;   Tongue Cancer
Interventions: Drug: carboplatin;   Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Drug: fluorouracil;   Drug: hydroxyurea;   Procedure: therapeutic conventional surgery;   Radiation: radiation therapy;   Radiation: hyperfractionated radiation therapy;   Other: laboratory biomarker analysis
15 Recruiting A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck
Conditions: Squamous Cell Carcinoma of the Oral Cavity;   Squamous Cell Carcinoma of the Oropharynx
Intervention: Drug: GC4419
16 Not yet recruiting Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer
Conditions: Stage III Squamous Cell Carcinoma of the Hypopharynx;   Stage III Squamous Cell Carcinoma of the Larynx;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Verrucous Carcinoma of the Larynx;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Verrucous Carcinoma of the Larynx;   Tongue Cancer
Interventions: Biological: cetuximab;   Drug: cisplatin;   Radiation: external beam radiation therapy;   Other: laboratory biomarker analysis
17 Not yet recruiting Exosome Testing as a Screening Modality for Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma
Condition: Oropharyngeal Cancer
Intervention:
18 Not yet recruiting Photodynamic Therapy With HPPH in Treating Patients With Squamous Cell Carcinoma of the Oral Cavity
Conditions: Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage I Squamous Cell Carcinoma of the Oropharynx;   Stage I Verrucous Carcinoma of the Oral Cavity;   Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage II Squamous Cell Carcinoma of the Oropharynx;   Stage II Verrucous Carcinoma of the Oral Cavity;   Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Verrucous Carcinoma of the Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Verrucous Carcinoma of the Oral Cavity
Interventions: Drug: HPPH;   Device: Light Infusion Therapy™;   Procedure: therapeutic conventional surgery
19 Recruiting A Phase II Study of Lymphodepletion Followed by Autologous Tumor-Infiltrating Lymphocytes and High-Dose Adesleukin for Human Papillomavirus-Associated Cancers
Conditions: Cervical Cancer;   Oropharyngeal Cancer;   Vaginal Cancer;   Anal Cancer;   Penile Cancer
Interventions: Drug: Fludarabine;   Drug: Cycolphosphamide;   Biological: Young TIL;   Drug: Aldesleukin
20 Recruiting A Pilot Study at a Single-Institution of Pregabalin in the Management of Mucositis Pain in Patients Undergoing Chemoradiation Therapy to the Head and Neck.
Conditions: Oropharyngeal Cancer;   Squamous Cell Carcinoma to the Head and Neck
Intervention: Drug: Lyrica 300 mg

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years